Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (July 2024)
22 slides from Oncosil Medical's investor presentation, Jul 23, 2024
Slide 1: OncoSil Limited – Developing pancreatic cancer treatment
Confidential For personal use only OncoSil Limited (ASX:OSL) Developing pancreatic cancer treatment Investor presentation – July 2024 Nigel Lange – CEO & Managing Director
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 3: A primer on pancreatic cancer
Confidential For personal use only A primer on pancreatic cancer
Slide 4: An enhanced pancreatic cancer treatment finally at hand
An enhanced pancreatic cancer treatment finally at hand Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% For personal use only All Cancers Incidence Testis Malignant Melanoma Prostate Hodgkin Lymphoma Breast Uterus • The prognosis for pancreatic cancer NHL Cervix patients has remained alm
Slide 5: Clinical Stages of Pancreatic Cancer
Clinical Stages of Pancreatic Cancer1 Tumour Size (LD) T1 2 cm T2 4 cm T3 For personal use only Stage IIa Stage Stage Stage 21% Stage I Stage IIb None: N0 RESECTABLE Lymph Nodes (regional) Cancer Common IA IB IIA bile duct patients diagnosed Pancrea Lymph 1–3: N1 Stage IIB [T1–3, N1] at Stage 1 and
Slide 6: Surgical Resection
Surgical Resection The only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC For personal use only % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curative intent (CT or ICT/CCRT)1,7,8,10 (usually CT
Slide 7: The OncoSil device
Confidential For personal use only The OncoSil TM device
Slide 8: OncoSil Device
OncoSil Device OncoSil is intended OncoSil is implanted directly For personal use only for the treatment of locally advanced into a pancreatic tumour via unresectable pancreatic cancer, injection under endoscopic in combination with gemcitabine-based ultrasound chemotherapy guidance 98% of all radia
Slide 9: Validating OncoSil device's effectiveness
Confidential For personal use only Validating OncoSilTM device’s effectiveness
Slide 10: PanCO study demonstrated positive safety and efficacy signals
PanCO study demonstrated positive safety and efficacy signals Of the many encouraging outcomes from the PanCO study1, four are particularly important: For personal use only Established safety profile: No evidence suggesting any additional risk from using OncoSil 90.5% of OncoSil treated patients had
Slide 11: TRIPP-FFX
TRIPP-FFX An open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 (OncoSil ) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX For personal use only chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma Objectiv
Slide 12: PANCOSIL (Investigator Initiated Study)
PANCOSIL (Investigator Initiated Study) Safety and feasibility of CT-guided percutaneous radionuclide therapy with the OncoSil device in patients with non-progressive locally advanced pancreatic cancer (PANCOSIL): an For personal use only open-label, single-arm phase 1-2 feasibility study To assess
Slide 13: Corporate overview and leadership team
Confidential For personal use only Corporate overview and leadership team
Slide 14: Leadership team
Leadership team For personal use only Nigel Lange Douglas Cubbin Gabriel Liberatore Peter Hall Managing Director & CEO Non-executive Chairman Non-executive Director To be Appointed Non-executive Director 30+ years experience in Experienced biopharmaceutical Dr Liberatore is an experienced by the end
Slide 15: Leadership team
Leadership team For personal use only David Turner Henk Tissing Christian Dal Cin Renzo DiCarlo Dr Jon Bell MD Head of Medical Affairs Director of Clinical Development Chief Financial Officer Head of Transformation Chief Medical Officer 40+ years experience in 25+ years industry Christian has over 2
Slide 16: FY 2024
Confidential For personal use only FY 2024
Slide 17: Achievements FY2024
Achievements FY2024 For personal use only PANCOSIL trial TRIPP study Innovation Funding Revised HDE dossier – 6 patients now up to 12 (NUB) approval for 84 completed – currently treated sites with German hospitals under final review prior to 31/80 patients FDA submission recruited Commencement of EU
Slide 18: Commercialisation strategy & investment thesis
Confidential For personal use only Commercialisation strategy & investment thesis
Slide 19: Targeted commercialisation strategy deliverables
Targeted commercialisation strategy deliverables For personal use only G-BA progressed to commercial agreement FDA processes advanced EU MDR Approval Re-engage TGA for approval in Australia following MDR approval A steady uplift in the number of commercial treatments utilising OncoSilTM de
Slide 20: Sites undertaking OncoSil Device treatments continue to grow
Sites undertaking OncoSilTM Device treatments continue to grow Sites undertaking OncoSilTM For personal use only Device treatments continue to grow
Slide 21: The OncoSil device is now in early-stage commercialisation
The OncosilTM device is now in early-stage commercialisation The OncoSil device, an effective treatment for locally advanced pancreatic cancer, is now penetrating its already large and continually growing target addressable markets For personal use only Many key components of commercialisation str
Slide 22: Developing pancreatic cancer treatment
For personal use only Developing pancreatic cancer treatment OncoSil Medical Limited (ASX:OSL) Investor Presentation July 2024 Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Media & Investor Enquiries The Capital Network Julia Maguire P: +61 2 8999 3699 E: julia@thecapitalnetwork.com